Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to compare the pharmacokinetics of capsule and tablet formulations of TA-8995 in healthy male subjects aged 18 to 55 years.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Xention Ltd

Criteria

Inclusion Criteria:

• Healthy males aged 18-55

• Body Mass Index (BMI) between 18.0 and 32.0 kg/m2, inclusive

Exclusion Criteria:

• Subject has a known hypersensitivity to any of the inactive ingredients of the study treatments.

• Subject has any other condition which, in the Investigator's opinion will interfere with the study.

• Subjects who are still participating in another clinical study (eg, attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) within 3 months or 5 half-lives (whichever is longer) prior to the first dose in this study.